The Future of Drug Delivery: From Infusion Centers to Wearable Biologics | Matthew Huddleston - Chief Commercial Officer, Enable Injections

Episode notes

Send us Fan Mail Some of the most important cancer and autoimmune disease drugs in the world still require patients to sit in infusion chairs for hours - but that model may be about to change entirely. Matthew Huddleston is Chief Commercial Officer at Enable Injections ( ), a medical device company focused on rethinking how large-volume biologic drugs are delivered to patients. Enable’s core technology, the enFuse® on-body delivery system, is designed to shift certain therapies from traditional intravenous infusion to subcutaneous, wearable administration - potentially transforming treatment from something that requires a clinic visit into something that can be done at home, more comfortably and more conveniently. What makes this particularly interesting is where Enable sits in the broader biopharma ecosystem. The company is actively partnering with major pharmaceutical innovators including Sanofi, Roche, Incyte, and Viridian Therapeutics to support the transition of complex biologics into subcutaneous delivery formats.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-DroryVentures from The Valley · on Biotech81 / 100
• The Frontier State of Nonprofit AcceleratorsThe Frontier State Podcast · on Biotech78 / 100
• Deep Tech Gold Rush: Smart Boom or Future Bust?Venture Unlocked · on Biotech71 / 100
• Why Customer Success Is the Next Major Category in MedTech with Rupal Ayer, Senior Director of Customer Success at SolventumOutcomes Rocket · on Medtech63 / 100
• #113 - What was Fred Hoch from TechNexus doing in his 20sinTheir20s · on Biotech57 / 100
• Building a Founder-First Innovation Ecosystem with John MacRitchie | BVZ Five Years BoldThe Business Leadership Podcast · on Medtech44 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100
• How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 100
• 55 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100
• How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences